BioCentury
ARTICLE | Clinical News

Vanda slides on tasimelteon discontinuation for MDD

February 1, 2013 1:49 AM UTC

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) slid $0.32 to $4.02 on Thursday after the company said it discontinued development of tasimelteon to treat major depressive disorder (MDD). The company made the decision after once-daily tasimelteon missed the primary endpoint vs. placebo in the Phase IIb/III MAGELLAN trial for MDD. The double-blind, U.S. trial enrolled 507 patients. ...